ImmunoGenesis

Immuno Genesis

Biotechnology, 300 the American Rd, Houston, Texas, 07950, United States, 11-50 Employees

immunogenesis.com

  • facebook
  • twitter
  • LinkedIn

Who is IMMUNOGENESIS

ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning the treatment of "cold" tumors, particularly of immune-excluded tumors. Immune-excluded tumors, ...

Read More

map
  • 300 the American Rd, Houston, Texas, 07950, United States Headquarters: 300 the American Rd, Houston, Texas, 07950, United States
  • 2019 Date Founded: 2019
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $250 Million to $500 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from IMMUNOGENESIS

ImmunoGenesis Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ImmunoGenesis

Answer: ImmunoGenesis's headquarters are located at 300 the American Rd, Houston, Texas, 07950, United States

Answer: ImmunoGenesis's official website is https://immunogenesis.com

Answer: ImmunoGenesis's revenue is $250 Million to $500 Million

Answer: ImmunoGenesis's SIC: 8731

Answer: ImmunoGenesis's NAICS: 541714

Answer: ImmunoGenesis has 11-50 employees

Answer: ImmunoGenesis is in Biotechnology

Answer: ImmunoGenesis contact info: Phone number: Website: https://immunogenesis.com

Answer: ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning the treatment of "cold" tumors, particularly of immune-excluded tumors. Immune-excluded tumors, which account for more than half of all cancers, are characterized by having mechanisms of resistance that suppress the immune response; this subgroup is resistant to current immunotherapies. ImmunoGenesis is creating therapies based on the pathology of these immune-excluded tumors that are rationally designed to overcome immune exclusion and thereby drive an effective immune response. We look at cold, immune-excluded tumors through a new lens, re-envisioning treatment with a deliberate drug development strategy based in cold tumor pathology.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access